Skip to main
  1. Stocks
  2. Outlook Therapeutics Inc
  3. Forecast
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is attractive because it has already secured marketing authorization for LYTENAVA in the European Union and United Kingdom, validating ONS-5010 clinically and commercially while creating an initial revenue base that is still early but expanding. The company’s FDA appeal win in May 2026 and BLA resubmission on June 1, 2026 materially de-risk the U.S. story, with a decision expected within 60 days and management preparing for a U.S. launch by the end of calendar 2026. With about $62.3 million in pro forma cash, $50 million to $75 million of first-year U.S. sales expected, and a path to more than $500 million in annual U.S. sales by 2030, the business has meaningful operating leverage if adoption and reimbursement progress as planned.

Bears say

Outlook Therapeutics is facing a deeply challenged approval path for ONS-5010, as the FDA issued Complete Response Letters on August 30, 2023, August 28, 2025, and December 31, 2025, despite the NORSE TWO pivotal trial meeting its safety and efficacy endpoints. The repeated setbacks reflect persistent regulatory and CMC concerns, with the most recent CRL citing a lack of substantial evidence of effectiveness and recommending additional confirmatory evidence, underscoring material execution risk around product approval and commercialization. Combined with balance sheet and liquidity risk, reimbursement uncertainty, and heavy competition in wet AMD, the company remains highly dependent on future regulatory success to justify its investment case.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

OTLK Analyst Forecast & Price Prediction

Get the latest OTLK stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OTLK

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


OTLK Analyst Forecast & Price Prediction

Get the latest OTLK stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OTLK

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OTLK stock data and trends